Roles of SAA,CRP and LYMPH# in clinical classification and efficiency evaluation of corona virus disease 2019

doi:10.3969/j.issn.1673-8640.2020.10.009

Abstract

Abstract:

Objective To study the roles of serum amyloid A（SAA）,C-reactive protein（CRP）and the absolute value of lymphocyte（LYMPH#） in clinical classification and efficiency evaluation of corona virus disease 2019（COVID-19）. Methods Totally,45 patients with COVID-19,including 31 cases of light type and 14 cases of severe type,which were all improved and discharged,were enrolled,and 50 suspected patients without severe acute respiratory syndrome coronavirus 2（SARS-CoV-2） infection were enrolled as disease control group. A total of 60 healthy subjects were enrolled as healthy control group. SAA,CRP and LYMPH# were determined. Results In severe type group,SAA,CRP and LYMPH# in light type group,disease control group and healthy control group had statistical significance（P<0.05）. CRP in light type group was lower than that in disease control group（P<0.05）,and there was no statistical significance for SAA and LYMPH# between the 2 groups（P>0.05）. SAA in light type group was higher than that in healthy control group（P<0.05）,and LYMPH# was lower（P<0.05）. There was no statistical significance for CRP between the 2 groups（P>0.05）. Compared with the time of admission,SAA and CRP in COVID-19 group were decreased（P<0.05）,and LYMPH# was increased（P<0.05）. Conclusions SAA,CRP and LYMPH# play roles in clinical classification and efficiency evaluation of COVID-19.

Key words: Serum amyloid A, C-reactive protein, Absolute value of lymphocyte, Corona virus disease 2019

CLC Number:

R446.1

TANG Shengyao, LIU Guosheng, CHU Zhihua, DU Guiyan, ZHOU Shuchu, ZHOU Fawei. Roles of SAA,CRP and LYMPH# in clinical classification and efficiency evaluation of corona virus disease 2019[J]. Laboratory Medicine, 2020, 35(10): 1005-1007.

Figures/Tables 2

References 10

[1]	姚宏武,索继江,杜明梅,等. 新型冠状病毒肺炎流行期间医院感染防控难点与对策[J]. 中华医院感染学杂志,2020,30(6):806-810.
[2]	国家卫生健康委员会. 新型冠状病毒肺炎诊疗方案(试行第六版). [EB/OL]. (2020-02-19)[2020-03-01]. .
[3]	钱扬会. 2019新型冠状病毒实验室检测与预防研究[J]. 检验医学与临床,2020,17(10):1457-1459.
[4]	LU R,ZHAO X,LI J,et al.Genomic characterisation and epidemiology of 2019 novel coronavirus:implications for virus origins and receptor binding[J]. Lancet,2020,395(10224):565-574.
[5]	REN L L,WANG Y M,WU Z Q,et al.Identification of a novel coronavirus causing severe pneumonia in human:a descriptive study[J]. Chin Med J(Engl),2020,133(9):1015-1024.
[6]	ZHOU P,YANG X,WANG X,et al. Discovery of a novel coronavirus associated with the recent pneumonia outbreak in humans and its potential bat origin[J/OL]. BioRxiv,2020. .
[7]	PIOTTI K C,YANTISS R K,CHEN Z,et al.Serum amyloid A immunohistochemical staining patterns in hepatitis[J]. Histopathology,2016,69(6):937-942.
[8]	LIANG Z,PAN H,WANG X,et al.Histopathological features and viral antigen distribution in the lung of fatal patients with enterovirus 71 infection[J]. Virol Sin,2018,33(3):278-281.
[9]	ELMASHAD G M,ELSAYED H M,OMAR Z A,et al.Evaluation of serum amyloid A protein as a marker in neonatal sepsis[J]. Menoufia Med J,2019,32(3):1094-1098.
[10]	付海卫,孔一名,李小波,等. SAA、CRP和ESR联合检测诊断AECOPD的临床价值[J]. 检验医学,2018,33(7):586-589.

组别	例数	SAA/（mg/L）	CRP/（mg/L）	LYMPH#/（×10⁹/L）
正常对照组	60	4.38±1.50	2.92±1.36	2.26±0.56
疾病对照组	50	77.90±18.31	39.96±14.74	1.23±0.26
COVID-19轻症组	31	96.66±56.88^*	3.43±1.27^#	1.08±0.38^*
COVID-19重症组	14	311.29±44.92^*#△	23.27±8.11^*#△	0.51±0.17^*#△

组别	例数	SAA/（mg/L）	CRP/（mg/L）	LYMPH#/（×10⁹/L）
正常对照组	60	4.38±1.50	2.92±1.36	2.26±0.56
疾病对照组	50	77.90±18.31	39.96±14.74	1.23±0.26
COVID-19轻症组	31	96.66±56.88^*	3.43±1.27^#	1.08±0.38^*
COVID-19重症组	14	311.29±44.92^*#△	23.27±8.11^*#△	0.51±0.17^*#△

项目	例数	SAA/ （mg/L）	CRP/（mg/L）	LYMPH#/（10⁹/L）
入院时	45	163.43±113.57	9.60±10.34	0.90±0.42
出院时	45	10.30±6.20	4.04±3.66	1.55±0.61
t值		9.43	5.29	12.21
P值		0.00	0.00	0.00

项目	例数	SAA/ （mg/L）	CRP/（mg/L）	LYMPH#/（10⁹/L）
入院时	45	163.43±113.57	9.60±10.34	0.90±0.42
出院时	45	10.30±6.20	4.04±3.66	1.55±0.61
t值		9.43	5.29	12.21
P值		0.00	0.00	0.00

[1]	CHU Ye, XIONG Chunxiang, HUANG Yu, ZENG Jiaxing, YI Bode, HUANG Nenggan, YANG Yifeng, YANG Feng. Role of nomogram models based on CAR and NLR in predicting 1-year mortality in elderly patients with hip fractures after surgery [J]. Laboratory Medicine, 2025, 40(9): 834-840.
[2]	YAO Yanhong, ZHAI Chunli. Predictive role of serum amyloid A and homocysteine on pregnancy outcome in patients with gestational diabetes mellitus [J]. Laboratory Medicine, 2025, 40(8): 751-756.
[3]	YIN Liangping, YUAN Yongming, QU Bin, LI Wenna, ZHANG Shu. Role of neutrophil CD64 absolute value determined by cell solid-phase chip method in bacterial infectious disease diagnosis [J]. Laboratory Medicine, 2025, 40(6): 571-575.
[4]	LI Yazhou, SU Min, ZHANG Jinghao, FANG Yi, WANG Su, WANG Shiwen, ZHAO Hu. Roles of single and combined determinations of CRP，HBP，CLR and HAR in the diagnosis of bloodstream infection in elderly patients [J]. Laboratory Medicine, 2025, 40(5): 489-492.
[5]	ZHANG Haoyang, LU Lin, ZONG Ming, HE Long, DING Yuanyuan, FAN Lieying. Diagnostic and predictive value of white blood cell population data in patients with sepsis [J]. Laboratory Medicine, 2025, 40(3): 271-277.
[6]	LI Minghong, MIN Cuili, GUO Qingbo, MA Lujuan. Predictive roles of serum 25（OH）D and SAA for the response to immunosuppressive therapy in autoimmune hepatitis [J]. Laboratory Medicine, 2025, 40(12): 1165-1170.
[7]	YUAN Yongcheng, LIU Shangjun. Roles of C-reactive protein/albumin ratio and neutrophil/lymphocyte ratio in predicting obstructive sleep apnea hypopnea syndrome with hypertension [J]. Laboratory Medicine, 2024, 39(7): 640-644.
[8]	WANG Tiankai, LIU Lin, JIN Peipei, WANG Fang, DING Ning. Clinical value of new neutrophil parameter NEU-X，NEU-Y and NEU-Z in diagnosis of sepsis [J]. Laboratory Medicine, 2024, 39(7): 682-686.
[9]	DAI Yao, LI Jiahui, XU Xiuhong. Prognosis evaluation model of children with Mycoplasma pneumoniae pneumonia based on MP DNA and peripheral blood inflammation indicators [J]. Laboratory Medicine, 2024, 39(6): 568-572.
[10]	ZHOU Yufei, LI Yunhui, LI Bingyi, HOU Qingxia. Relation of C-reactive protein-to-albumin ratio and systemic immune-inflammation index with pathological characteristics and prognosis of serous ovarian cancer patients [J]. Laboratory Medicine, 2024, 39(4): 363-368.
[11]	SUN Kangde, YU Zhongmin, YAN Yuzhong. Roles on early diagnosis and prognosis of different infection indicators for bloodstream infection [J]. Laboratory Medicine, 2024, 39(3): 222-226.
[12]	YANG Jing, LIU Huapeng, LIU Ni. Role of serum MyD88 and TRAF-6 combined determination in diagnosis and prognosis of severe acute respiratory tract infection in children [J]. Laboratory Medicine, 2024, 39(3): 237-242.
[13]	WU Caorong, CUI Wen, TANG Binbin, HE Jingjing, LAI Zhikun. Correlations between the ratio of C-reactive protein to prealbumin and the prognosis of patients with acute heart failure [J]. Laboratory Medicine, 2023, 38(6): 579-583.
[14]	XIANG Jin, LIU Aiping, HU Yao, WU Zhiyuan, CAO Guojun, GUAN Ming. ANA profiles in COVID-19 patients and influence of serum heat-inactivation on ANA determination [J]. Laboratory Medicine, 2023, 38(12): 1141-1146.
[15]	YUE Caidie, LI Junyan, DING Aijun, XIE Li, ZENG Weikun. Research progress of rapid determination methods for SARS-CoV-2 antigen [J]. Laboratory Medicine, 2023, 38(1): 87-93.